Field Medical today announced the successful closing of $40 million in Series A financing to support its cardiac pulsed field ablation (PFA) platform with an initial focus on ventricular tachycardia (VT).
The funding will support the completion of two pilot studies – VCAS for VT and Field PULSE for atrial fibrillation (AF) – as well as continued development of Field's commercial PFA system and operational scale-up in preparation for VERITAS, the company's pivotal trial focused on VT.
"This financing is a pivotal milestone as we advance in redefining how electrophysiologists approach ablation therapy," said Steven Mickelsen, M.D., founder and chief executive officer of Field Medical. "With the support of our investors, we are accelerating the development of the FieldForce™ Ablation System, building on early clinical evidence, and moving closer to our commercial goal of expanding access to next-generation PFA solutions for cardiac ablation."
"We are encouraged by the strong support and confidence from both new investors and our reinvesting seed-round investor base," said Oskar Dadason, chief financial officer. "This funding enables us to execute our strategic plan with speed and focus as we transition from early-stage innovation into commercial readiness."
Field Medical is developing technology for the treatment of all cardiac arrhythmias, including VT and AF. The FieldForce Ablation System, featuring a contact force focal PFA catheter, enables an instantaneous ablation workflow, with therapy delivered in a fraction of a second. Recent results from the VCAS (VT) and PULSE (AF) pilot studies demonstrate the system's versatility. Powered by FieldBending, the company's proprietary technology that delivers brief, high-intensity electric fields, the system is positioned as a single, advanced solution for treating a full spectrum of cardiac arrhythmias.
